Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | DHODH | Q02127 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.57 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606143 | 0.82 | ALDH1A1 (1.00) | ALDH1A1TSHRHPGDL3MBTL1DHODH | |
| SCHEMBL53323 | 0.82 | ALDH1A1 (1.00) | ALDH1A1TSHRHPGDL3MBTL1DHODH | |
| SCHEMBL7932159 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1DHODH | |
| SCHEMBL4003611 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1LMNA | |
| SCHEMBL4009579 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1LMNA | |
| SCHEMBL3729153 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1DHODH | |
| SCHEMBL659023 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1LMNA | |
| SCHEMBL14414533 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1DHODH | |
| SCHEMBL20990440 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1LMNA | |
| SCHEMBL2213195 | 0.82 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDL3MBTL1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | ALDH1A1 4444/4885TSHR 3971/4885HPGD 2923/4885 |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | ALDH1A1 2744/4885TSHR 471/4885HPGD 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.